Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tarloxotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 0.69 |
| ▸ | ERBB2 known ✓ | P04626 | 6/20 | 0.48 |
| ▸ | ERBB4 known ✓ | Q15303 | 5/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarloxotinib SCHEMBL29373183 | 1.00 | EGFR (0.69) | EGFRERBB2ERBB4JAK3 | |
| Tarloxotinib SCHEMBL11902818 | 0.99 | EGFR (0.70) | EGFRERBB2ERBB4JAK3 | |
| Tarloxotinib SCHEMBL17873943 | 0.99 | EGFR (0.70) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL11903065 | 0.94 | EGFR (0.70) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL11902922 | 0.93 | EGFR (0.72) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL11902840 | 0.93 | EGFR (0.68) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17503016 | 0.92 | EGFR (0.69) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL867357 | 0.92 | EGFR (0.70) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL11903184 | 0.90 | EGFR (0.70) | EGFRERBB2ERBB4JAK3 | |
| Bromide SCHEMBL11902541 | 0.90 | EGFR (0.64) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| CN-119907692-A | Isolated targeted delivery system for the treatment of gliomas | 塞尔丽思股份公司 | 2025-04-29 | — | — | CN | claimed |
| WO-2024133541-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | CELLIS SP. Z O.O. [LTD.] (PL) | 2024-06-27 | — | — | WO | claimed |
| EP-3310904-B1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2024-04-03 | — | — | EP | claimed |
| WO-2024056413-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2024-03-21 | — | — | WO | claimed |
| CN-114224894-A | Kinase inhibitor prodrugs for the treatment of cancer | 奥克兰联合服务有限公司 | 2022-03-25 | — | — | CN | claimed |
| US-20260138982-A1 | Biaryl Acid Compounds | PFIZER INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026105052-A1 | BIARYL ACID COMPOUNDS | PFIZER INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2020-08-27 | — | — | US | disclosed |
| EP-3679063-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | The Regents of The University of Colorado, A Body Corporate (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019051155-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20170360790-A1 | KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138982-A1 | Biaryl Acid Compounds | PIK3R1, PIK3R3, PIK3R5 | EGFR 106/4885ERBB2 41/4885ERBB4 440/4885 |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CD47, TFRC, L1CAM | EGFR 311/4885ERBB2 499/4885ERBB4 1540/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | EGFR 2523/4885ERBB2 2055/4885ERBB4 2049/4885 |
| US-20170360790-A1 | KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER | TK1, TTK, MAP3K20 | EGFR 351/4885ERBB2 82/4885ERBB4 116/4885 |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | EGFR, BRCA1, ERBB2 | EGFR 1/4885ERBB2 3/4885ERBB4 14/4885 |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | EGFR 482/4885ERBB2 685/4885ERBB4 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.